What is the GMP of Q-Line Biotech IPO today?

The Grey Market Premium (GMP) for Q-Line Biotech IPO is currently ₹129. With an upper price band of ₹343, the estimated listing price is ₹472 per share, reflecting an expected listing gain of ~37.61%. Grey market premiums can fluctuate based on market sentiment and subscription demand.

What is the price band and lot size for Q-Line Biotech IPO?

The price band for Q-Line Biotech IPO is ₹326 to ₹343 per equity share. The minimum lot size is 400 shares, which requires a minimum retail application investment of ₹1,37,200.

What are the important dates for Q-Line Biotech IPO?

Q-Line Biotech IPO opens for subscription on 2026-05-21T00:00:00 and closes on 2026-05-25T00:00:00. The basis of allotment is scheduled for 2026-05-26T00:00:00, and shares are expected to list on 2026-05-29T00:00:00 on BSE, NSE.

How can I check the allotment status for Q-Line Biotech IPO?

You can check Q-Line Biotech IPO allotment status on the registrar's official portal (Purva Sharegistry India Pvt Ltd) or through the official BSE and NSE IPO allotment status pages using your PAN number or Application number.

How to apply for Q-Line Biotech IPO?

Investors can apply for Q-Line Biotech IPO online through ASBA (Application Supported by Blocked Amount) via their internet banking account, or via UPI using authorized stockbroking platforms like Zerodha, Groww, Angel One, and Upstox.

When does the Q-Line Biotech IPO open and close?

The IPO opens on 21 May 2026, and closes on 25 May 2026.

What is Q-Line Biotech IPO price band?

The issue price band is ₹326.00 to ₹343.00 per equity share.

What is the Q-Line Biotech IPO lot size?

The minimum lot size is 400 shares per application.

What is the Q-Line Biotech IPO allotment date?

The allotment is scheduled on 26 May 2026.

Q-Line Biotech IPO Details - Dates, Price Band, Issue Size

All IPOs

Issue Size

214.48 Cr

Price Band

₹326.00 - ₹343.00

Lot Size

400 Shares

Min Investment

₹2,74,400

GMP

₹129

Subscription

102.42x

₹14,609.48 Cr

21 May 2026

IPO Opens

COMPLETED

25 May 2026

IPO Closes

COMPLETED

26 May 2026

Basis of Allotment

COMPLETED

27 May 2026

Refunds

COMPLETED

27 May 2026

Demat Credit

COMPLETED

29 May 2026

Listing

COMPLETED

IPO Timeline

IPO OpensDONE

21 May 2026

IPO ClosesDONE

25 May 2026

Basis of AllotmentDONE

26 May 2026

RefundsDONE

27 May 2026

Demat CreditDONE

27 May 2026

ListingDONE

29 May 2026

About Q-Line Biotech IPO

Q-Line Biotech IPO open date is May 21, 2026 and the IPO will close on May 25, 2026. Q-Line Biotech IPO is a Book build Issue. The company to raise around ₹214.48 crores via IPO that comprises fresh issue of ₹214.48 crores and offer for sale up to [.] equity shares with face value of ₹10 each.

Q-Line Biotech IPO price band is ₹326 to ₹343 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Q-Line Biotech IPO to list on NSE SME on 2026. The allotment of Q-Line Biotech IPO date is May 26, 2026.

The company reported revenue of ₹322.58 crores in 2025 against ₹206.45 crores in 2024. The company reported profit of ₹28.13 crores in 2025 against profit of ₹34.44 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.

IPO Details

Q-Line Biotech IPO Details and Specifications
IPO Date	21 May 2026 to 25 May 2026
Face Value	₹10 Per Share
Price Band	₹326.00 - ₹343.00
Lot Size	400 Shares
Total Issue Size	Approx 214.48 Cr 62,53,200 Equity Shares
Fresh Issue	Approx 214.48 Cr 62,53,200 Equity Shares
Offer for Sale	Approx 0.00 Cr 0 Equity Shares
Retail Portion	35%
Sale Type	Fresh Issue
Issue Type	Bookbuilding IPO
Listing Date	29 May 2026
Listing At	NSE
Total Subscription Amount	₹14,609.48 Cr

Issue Reservation

Investor Category	Shares Offered	% Net Issue
QIB	29,69,200	49.99%
- Anchor	17,81,200	0.00%
- QIB (Ex. Anchor)	11,88,000	0.00%
NII	8,91,600	15.01%
- bNII > ₹10L	5,94,400	0.00%
- sNII < ₹10L	2,97,200	0.00%
Retail	20,79,200	35.00%
Share Holders	TBA	0.00%
Market Maker	3,13,200	0.00%
Total	62,53,200	100.00%

IPO Lot Size

Application	Lots	Shares	Amount
Individual investors (Retail) (Min)	2	800	₹2,74,400
Individual investors (Retail) (Max)	2	800	₹2,74,400
S-HNI (Min)	3	1,200	₹4,11,600
S-HNI (Max)	7	2,800	₹9,60,400
B-HNI (Min)	8	3,200	₹10,97,600

About Company

Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry. The firm is known for manufacturing and supplying In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments. The firm has been known to offer high-quality products and services at an affordable price range.

Contact Details

Q-Line Biotech Ltd.

298-281,

Transport Nagar,

Kanpur Road Adjacent Transport Nagar Metro Station

Lucknow, Uttar Pradesh, 226012

+91 522-2435570

compliance@qlinebiotech.com

Visit Website

Registrar

Purva Sharegistry India Pvt Ltd

022-41343255

support@purvashare.com

Lead Managers

Hem Securities Ltd

Share India Capital Services Pvt Ltd

Day-wise GMP Trend

Date & Time	GMP (₹)	Est. Listing Price	Est. Gain (%)	Est. Profit / Lot (₹)
29-May-2026 12:00 PM	+₹129	₹472	+37.61%	₹51,600
28-May-2026 12:00 PM	+₹124	₹467	+36.15%	₹49,600
27-May-2026 12:00 PM	+₹108	₹451	+31.49%	₹43,200
26-May-2026 12:00 PM	+₹110	₹453	+32.07%	₹44,000
25-May-2026 12:00 PM	+₹99	₹442	+28.86%	₹39,600
23-May-2026 12:00 PM	+₹130	₹473	+37.90%	₹52,000
22-May-2026 12:00 PM	+₹120	₹463	+34.99%	₹48,000
21-May-2026 12:00 PM	+₹125	₹468	+36.44%	₹50,000
20-May-2026 12:00 PM	+₹110	₹453	+32.07%	₹44,000
19-May-2026 12:00 PM	+₹97	₹440	+28.28%	₹38,800
18-May-2026 12:00 PM	+₹65	₹408	+18.95%	₹26,000

Subscription Status

Category	Subscription (x)	Shares Offered	Shares bid for	Total Amount (₹ Cr)
QIB (Ex. Anchor)	123.94x	11,88,000	14,72,37,200	₹5,050.24 Cr
NII	145.98x	8,91,600	13,01,53,600	₹4,464.27 Cr
bNII > ₹10L	178.29x	5,94,400	10,59,76,000	₹3,634.98 Cr
sNII < ₹10L	81.35x	2,97,200	2,41,77,600	₹829.29 Cr
Retail	71.44x	20,79,200	14,85,41,600	₹5,094.98 Cr
Total	102.42x	41,58,800	42,59,32,400	₹14,609.48 Cr

Objects of the Issue

01 To meet Working Capital requirements : 93.50 Cr
02 Repayment of certain borrowing availed by the Company, in part or full : 90.00 Cr
03 General Corporate Purpose : 5.10 Cr
04 Issue Expenses : 25.89 Cr

Company Financials

Period Ended	31 DEC 2025	31 MAR 2025	31 MAR 2024
Total Income	236.50	322.58	206.45
Profit After Tax	38.69	28.13	34.44
EBITDA	64.23	71.32	37.63
NET Worth	229.16	189.95	161.81
Reserves and Surplus	212.89	188.37	160.24
Total Borrowing	243.85	164.95	96.91

Amount in ₹ Crore

IPO Valuation - KPI

KPI	31 Mar 2025
ROCE	23.74%
Debt/Equity Ratio	0.87
Return on Net Worth (RoNW)	23.74%
PAT Margin	8.97%
EBITDA Margin	22.73%
Net Asset Value (NAV)	₹120.60
Earning Per Share (EPS)	₹28.63

Peer Comparison

Peer comparison data will be updated soon.

IPO Anchor Investors

Anchor Investors Letter (PDF)

Promoters and Holding Pattern

Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty, Abhay Agrawal are the company's promoters of Q-Line Biotech.

Particular	Pre IPO	Post IPO
Promoter and Promoter Group	96.77%	67.51%
Others*	3.23%	32.49%

Strengths

Q-Line Biotech claims to have established manufacturing and R&D capabilities in the in-vitro diagnostics (IVD) segment. The company operates four manufacturing facilities, including three in Lucknow and one in Delhi, with installed capacity for manufacturing reagent kits and diagnostic analysers. It also claims to have a dedicated R&D team of 19 scientists and engineers working on product development, reverse engineering, and validation.
The company has developed a diversified product portfolio across multiple diagnostic categories. Its offerings include clinical chemistry reagents, haematology reagents, rapid and Elisa kits, molecular diagnostic products, diagnostic analysers, consumables, and annual maintenance services for diagnostic equipment. Reagents and diagnostic instruments together contributed a major portion of its revenue in recent financial years.
Q-Line Biotech claims to have expanded its manufacturing infrastructure through additional facilities commissioned in 2026. According to the prospectus, the expansion is expected to increase production capacity for clinical chemistry reagents, Rapid/Elisa kits, glucometer devices, and glucometer strips. The company is also developing and manufacturing certain “Make in India” diagnostic analysers and laboratory devices.
The company is ISO 13485:2016 certified for its quality management systems for medical devices at its Lucknow manufacturing facility located at Khasra No. 3105, Amausi, Sarojini Nagar, Lucknow. It also states that its facilities have undergone inspections and audits by regulatory authorities and certification agencies, including CDSCO, State Drug Authorities, Intertek, URS Certification Limited, and certain European regulatory agencies.
Q-Line Biotech claims to have a distribution and service network spread across multiple regions in India. As of March 31, 2026, the company had 283 distributors, 103 sales personnel, and 35 service engineers supporting laboratories, hospitals, institutions, and distributors. The company states that it markets products across around 26 states and Union Territories.
Q-Line Biotech is led by promoters and senior management with experience in the diagnostic and healthcare industry. Promoter and chairman & managing director Saurabh Garg has over 31 years of experience in the healthcare and diagnostics sector, while other senior management personnel oversee areas including manufacturing, R&D, operations, finance, and strategic collaborations.
The company has reported growth in revenue and operating profitability over the last few financial years. Revenue from operations increased from Rs 182.74 crore in FY23 to Rs 203.65 crore in FY24, and then to Rs 313.78 crore in FY25, while EBITDA increased from Rs 32.98 crore in FY23 to Rs 37.62 crore in FY24 and Rs 71.32 crore in FY25. EBITDA margins also improved from 18.05% in FY23 to 22.73% in FY25.

Risks

The company’s business is significantly dependent on its distributor network, including group entity POCT Services. The top distributor contributed Rs 151.94 crore (65.37%), Rs 197.48 crore (62.94%), Rs 105.22 crore (51.67%), and Rs 69.26 crore (37.90%) to revenue during the period ended December 31, 2025, in FY25, FY24, and FY23, respectively. Further, the top 10 distributors contributed Rs 187.36 crore (80.61%), Rs 257.79 crore (82.16%), Rs 155.03 crore (76.13%), and Rs 138.25 crore (75.66%) during the same periods. Loss of any of these distributors, failure to renew agreements on favourable terms, or the inability to maintain after-sales support may hurt the company’s business operations and financial condition.
The company is dependent on a limited number of suppliers for the procurement of raw materials and traded diagnostic instruments. For raw materials, the top three suppliers contributed Rs 10.27 crore (22.57%), Rs 6.56 crore (14.41%), and Rs 4.36 crore (9.59%) of total raw material purchases during the period ended December 31, 2025. In the instruments segment, the top supplier alone contributed Rs 12.65 crore (47.21%), Rs 19.71 crore (57.08%), Rs 39.34 crore (61.70%), and Rs 10.87 crore (30.87%) of instrument purchases in the period ended December 31, 2025, FY25, FY24, and FY23, respectively. Any disruption in supplies, increase in procurement costs, supply shortages, or preferential pricing offered to competitors could adversely affect the company’s operations, profitability, and customer servicing capabilities.
The company’s operations are dependent on obtaining, renewing, and maintaining multiple statutory approvals, licenses, registrations, and regulatory clearances across its manufacturing facilities, warehouses, and branch offices. The company has several approvals that are pending, yet to be applied for, or are still held in its previous name, including GST registration, import licences, warehouse licences under the Drugs and Cosmetics Rules, fire safety approvals, trade licences, and R&D recognition certificates. Any delay, suspension, non-renewal, cancellation, or failure to obtain these approvals could result in penalties, regulatory actions, disruption in operations, restrictions on imports, lease termination of certain facilities, or temporary suspension of business activities, which may adversely affect the company’s business and financial condition.
A significant portion of the company’s operations and revenue is concentrated in North India, particularly in Uttar Pradesh. The Northern region contributed Rs 252.62 crore (80.51%), Rs 159.22 crore (78.19%), and Rs 142.30 crore (77.87%) to revenue in FY25, FY24, and FY23, respectively. Further, Uttar Pradesh alone contributed Rs 226.72 crore (72.25%), Rs 134.31 crore (65.95%), and Rs 125.20 crore (68.51%) during the same periods. Any adverse political, economic, social, or regional developments in North India, particularly in Uttar Pradesh, could negatively impact the company’s business operations and financial performance.
The company requires substantial working capital to manage day-to-day operations, including procurement of raw materials, freight expenses, labour costs, and other operational requirements. Its working capital increased from Rs 37.28 crore in FY23 to Rs 120.74 crore in FY25 and stood at Rs 201.66 crore as of December 31, 2025. Any inability to secure sufficient working capital facilities or additional financing on favourable terms could affect the company’s ability to meet customer demand, manage operations efficiently, and support future growth plans.
The company has reported negative cash flows from operating activities in three of the last four reported periods. Net cash flow from operating activities stood at negative Rs 33.11 crore, negative Rs 1.32 crore, and negative Rs 24.18 crore in the period ended December 31, 2025, FY25, and FY24, respectively, compared to a positive cash flow of Rs 24.97 crore in FY23. The negative operating cash flows were mainly due to higher working capital requirements, increased credit periods offered to customers, and higher inventory levels. If the company continues to generate negative operating cash flows, it may face pressure on liquidity, working capital management, and future expansion plans.

Frequently Asked Questions (FAQ)

Comments0

Join the discussion

Please sign in to leave a comment or reply.

Sorted by

Loading IPO Details...

About Q-Line Biotech IPO

IPO Details

Q-Line Biotech IPO Details and Specifications
IPO Date	21 May 2026 to 25 May 2026
Face Value	₹10 Per Share
Price Band	₹326.00 - ₹343.00
Lot Size	400 Shares
Total Issue Size	Approx 214.48 Cr 62,53,200 Equity Shares
Fresh Issue	Approx 214.48 Cr 62,53,200 Equity Shares
Offer for Sale	Approx 0.00 Cr 0 Equity Shares
Retail Portion	35%
Sale Type	Fresh Issue
Issue Type	Bookbuilding IPO
Listing Date	29 May 2026
Listing At	NSE
Total Subscription Amount	₹14,609.48 Cr

Investor Category

Shares Offered

% Net Issue

QIB

29,69,200

49.99%

- Anchor

17,81,200

0.00%

- QIB (Ex. Anchor)

11,88,000

0.00%

NII

8,91,600

15.01%

- bNII > ₹10L

5,94,400

0.00%

- sNII < ₹10L

2,97,200

0.00%

Retail

20,79,200

35.00%

Share Holders

TBA

0.00%

Market Maker

3,13,200

0.00%

Total

62,53,200

100.00%

Application

Lots

Amount

Individual investors (Retail) (Min)

800

₹2,74,400

Individual investors (Retail) (Max)

800

₹2,74,400

S-HNI (Min)

1,200

₹4,11,600

S-HNI (Max)

2,800

₹9,60,400

B-HNI (Min)

3,200

₹10,97,600

About Company

Contact Details

Q-Line Biotech Ltd.

298-281,

Transport Nagar,

Kanpur Road Adjacent Transport Nagar Metro Station

Lucknow, Uttar Pradesh, 226012

+91 522-2435570

compliance@qlinebiotech.com

Visit Website

Date & Time

GMP (₹)

Est. Listing Price

Est. Gain (%)

Est. Profit / Lot (₹)

29-May-2026 12:00 PM

+₹129

₹472

+37.61%

₹51,600

28-May-2026 12:00 PM

+₹124

₹467

+36.15%

₹49,600

27-May-2026 12:00 PM

+₹108

₹451

+31.49%

₹43,200

26-May-2026 12:00 PM

+₹110

₹453

+32.07%

₹44,000

25-May-2026 12:00 PM

+₹99

₹442

+28.86%

₹39,600

23-May-2026 12:00 PM

+₹130

₹473

+37.90%

₹52,000

22-May-2026 12:00 PM

+₹120

₹463

+34.99%

₹48,000

21-May-2026 12:00 PM

+₹125

₹468

+36.44%

₹50,000

20-May-2026 12:00 PM

+₹110

₹453

+32.07%

₹44,000

19-May-2026 12:00 PM

+₹97

₹440

+28.28%

₹38,800

18-May-2026 12:00 PM

+₹65

₹408

+18.95%

₹26,000

Q-Line Biotech IPO Details

About Q-Line Biotech IPO

IPO Details

Issue Reservation

IPO Lot Size

About Company

Day-wise GMP Trend

Objects of the Issue

Company Financials

IPO Valuation - KPI

Peer Comparison

IPO Anchor Investors

Promoters and Holding Pattern

Strengths

Risks

Frequently Asked Questions (FAQ)

When does the Q-Line Biotech IPO open and close?

What is Q-Line Biotech IPO price band?

What is the Q-Line Biotech IPO lot size?

What is the Q-Line Biotech IPO allotment date?

What is the Q-Line Biotech IPO listing date?

What is the minimum investment required in Q-Line Biotech IPO?

Join the discussion

Q-Line Biotech IPO Details

About Q-Line Biotech IPO

IPO Details

Issue Reservation

IPO Lot Size

About Company

Day-wise GMP Trend

Objects of the Issue

Company Financials

IPO Valuation - KPI

Peer Comparison

IPO Anchor Investors

Promoters and Holding Pattern

Strengths

Risks

Frequently Asked Questions (FAQ)

When does the Q-Line Biotech IPO open and close?

What is Q-Line Biotech IPO price band?

What is the Q-Line Biotech IPO lot size?

What is the Q-Line Biotech IPO allotment date?

What is the Q-Line Biotech IPO listing date?

What is the minimum investment required in Q-Line Biotech IPO?

Join the discussion